Compare Recursion Pharmaceuticals Inc (RXRX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs DENTSPLY SIRONA Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.70B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| RXRX | XRAY | |
|---|---|---|
Market Cap | $2.31B | $1.70B |
Volume | 40,478,768 | 4,220,050 |
Sector | Health | Health |
52-Week High | $6.79 | $14.68 |
52-Week Low | $2.84 | $8.52 |
Typical Hold Time | 22 Days | 72 Days |
Enterprise Value | $1.83B | $3.78B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
DENTSPLY SIRONA (XRAY) trades at $8.69, near its 52-week low, with bearish technical signals and declining revenue trends. The company reported Q2 2026 earnings beat but faces margin pressure and negative profitability metrics. Recent news highlights institutional stake increases and ongoing restructuring efforts amid challenging dental market conditions.
The stock presents a high-risk opportunity with analyst consensus target of $13.40 suggesting 54% upside potential. However, persistent net losses, declining revenue, and bearish technical indicators warrant caution. Recovery depends on successful execution of turnaround initiatives and market share stabilization in competitive dental equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
